News
| 07 Feb 2019 | |
| 05 Feb 2019 | |
| 07 Jan 2019 |
News & Events
Idorsia announced
Full Year 2018
Results
News & Events
Investor Webcast
Phase 3 investigation of
aprocitentan for resistant
hypertension management
News & Events
Investor Webcast
Phase 3 investigation of
clazosentan for patients with
cerebral vasospasm
News & Events
Investor Webcast
Phase 3 investigation of
ACT-541468 for patients with
insomnia
News & Events
Investor Webcast
Phase 3 investigation of
lucerastat for patients with
Fabry disease
Events
| Event | When |
| First Quarter 2019 Financial Results reporting* | April 18, 2019 |
| Annual General Meeting of Shareholders 2019 | May 3, 2019 |
| Half-Year 2019 Financial Results reporting* | July 23, 2019 |
| Nine-months 2019 Financial Results reporting* | October 22, 2019 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Full Year 2018 Financial Results
Idorsia published its full year financial results on Thursday February 7, 2019.
Half Year 2018 Financial Results
Idorsia published its half year financial results 2018 on Tuesday 24 July 2018.
Phase 3 initiation: Aprocitentan for resistant hypertension management
In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.
Phase 3 Advancing: Clazosentan for cerebral vasospasm
In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.
Phase 3 initiation: ACT-541468 for insomnia
In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of ACT-541468, a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia.
Phase 3 initiation: Lucerastat for Fabry disease
In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.
Share this page:
Contact
Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland
- +41 58 844 10 10
- Contact us online
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.